Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The clinical-trial record is replaced by a 403 Forbidden message, and an NIH notice about a terminology transition appears at the top of the page.
    Difference
    18%
    Check dated 2026-10-21T20:57:08.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The MIRASOL clinical trial record is now displayed, including study design and results, participant eligibility, locations, and study documents.
    Difference
    100%
    Check dated 2026-10-14T20:57:40.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The site footer’s revision number changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T21:45:01.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error with a minimal header and a Home link. This indicates the study record content is currently unavailable due to access restrictions.
    Difference
    18%
    Check dated 2026-09-23T21:53:38.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Revision updated to v3.7.0, indicating the latest version of the study documents. This appears to be a versioning update rather than a substantive change to the study content.
    Difference
    0.0%
    Check dated 2026-09-16T22:06:21.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.5 to v3.6.6, indicating the latest version of the study record.
    Difference
    0.0%
    Check dated 2026-09-02T19:51:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.